Occidental Petroleum announced it will sell its chemical division, OxyChem, to Berkshire Hathaway for $9.7 billion in cash, one of the largest energy-chemical divestitures of 2026.
Occidental shares declined 2.3% on the announcement, a muted reaction to a deal that reshapes the company’s portfolio. The sale is expected to strengthen the balance sheet, with $9.7 billion in cash proceeds giving the company room to pay down debt.
The deal could mark the last major acquisition under Warren Buffett’s leadership at Berkshire Hathaway, adding a layer of history to the transaction. Completion is subject to customary closing conditions.
Why Occidental is selling OxyChem
The company has been streamlining its portfolio amid elevated energy prices, and OxyChem was the natural piece to sell. The chemical division is a solid business, but it is not core to an oil and gas producer. Selling it for $9.7 billion in cash lets Occidental focus on what it does best.
The timing fits the market. Chemical assets are attracting strong prices, and Berkshire Hathaway is a buyer that can write a $9.7 billion check without blinking. For the seller, the sale converts a non-core division into cash at a moment when cash is king.
The company did not disclose a detailed use of proceeds, but the cash is expected to strengthen the balance sheet. The producer has carried heavy debt since its big acquisitions, and $9.7 billion goes a long way toward lightening that load.
What Berkshire Hathaway gets in the OxyChem deal
Berkshire Hathaway is buying a steady, cash-generating chemical business. OxyChem makes basic chemicals and vinyls used across manufacturing and construction, the kind of unglamorous industrial business Buffett has always liked. It fits the Berkshire mold: simple, profitable, and built to last.
The $9.7 billion price tag makes it one of the biggest deals of Buffett’s late tenure. If it proves to be the last major acquisition under his leadership, it would be a fitting coda, a classic Berkshire purchase of a real business with real cash flows.
Berkshire’s industrial portfolio already includes chemical and manufacturing operations, so OxyChem will have company. The conglomerate’s permanent-capital structure is built for exactly this kind of asset, one that compounds quietly over decades.
How the Occidental deal fits the energy market
The sale is one of the largest energy-chemical divestitures of 2026, and it reflects a wider trend. Oil producers are shedding non-core assets while prices are high, locking in value before the cycle turns. Occidental is following the playbook.
Elevated energy prices have given producers strong cash flows, but they have also raised questions about how long the good times last. Selling OxyChem now lets the company bank $9.7 billion rather than betting the chemical cycle stays strong.
The announcement came during a busy US corporate news day on Friday, which may explain the muted 2.3% decline in Occidental shares. Investors had plenty to digest, and a portfolio-shaping sale can read as either discipline or a lack of better options.
What happens next for Occidental
The deal still needs to clear customary closing conditions, and the companies gave no firm timeline for completion. Deals of this size usually take months to close, and regulatory clearance is typically part of the process. Once closed, the company will be a leaner, more focused oil and gas producer with a stronger balance sheet.
The $9.7 billion in proceeds gives management options: pay down debt, return cash to shareholders, or fund drilling. The market will be watching which path it chooses. For now, the company has traded a chemical division for financial flexibility, and the bet is that focus pays.
Occidental announced the deal on Friday, Oct 23, capping one of the busiest corporate news days of the year. The sale ranks among the largest energy-chemical divestitures of 2026, leaving the company with a cleaner balance sheet and a narrower focus on oil and gas. Investors will get the next update when the deal closes or when the company reports its next quarterly results.